Posted by Michael Wonder on 13 Sep 2023
Formycon announces file acceptance for FYB203, a biosimilar candidate to Eylea (aflibercept), by the US FDA
29 August 2023 - Formycon and its license partner Klinge Biopharma announce that the US FDA has accepted the biologics license application for FYB203, a biosimilar candidate to Eylea (aflibercept), for review.
The agency assigned a target action date of June 2024.
